Cargando…
Clinically Interpretable Radiomics-Based Prediction of Histopathologic Response to Neoadjuvant Chemotherapy in High-Grade Serous Ovarian Carcinoma
BACKGROUND: Pathological response to neoadjuvant treatment for patients with high-grade serous ovarian carcinoma (HGSOC) is assessed using the chemotherapy response score (CRS) for omental tumor deposits. The main limitation of CRS is that it requires surgical sampling after initial neoadjuvant chem...
Autores principales: | , , , , , , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9243357/ https://www.ncbi.nlm.nih.gov/pubmed/35785153 http://dx.doi.org/10.3389/fonc.2022.868265 |
_version_ | 1784738288803774464 |
---|---|
author | Rundo, Leonardo Beer, Lucian Escudero Sanchez, Lorena Crispin-Ortuzar, Mireia Reinius, Marika McCague, Cathal Sahin, Hilal Bura, Vlad Pintican, Roxana Zerunian, Marta Ursprung, Stephan Allajbeu, Iris Addley, Helen Martin-Gonzalez, Paula Buddenkotte, Thomas Singh, Naveena Sahdev, Anju Funingana, Ionut-Gabriel Jimenez-Linan, Mercedes Markowetz, Florian Brenton, James D. Sala, Evis Woitek, Ramona |
author_facet | Rundo, Leonardo Beer, Lucian Escudero Sanchez, Lorena Crispin-Ortuzar, Mireia Reinius, Marika McCague, Cathal Sahin, Hilal Bura, Vlad Pintican, Roxana Zerunian, Marta Ursprung, Stephan Allajbeu, Iris Addley, Helen Martin-Gonzalez, Paula Buddenkotte, Thomas Singh, Naveena Sahdev, Anju Funingana, Ionut-Gabriel Jimenez-Linan, Mercedes Markowetz, Florian Brenton, James D. Sala, Evis Woitek, Ramona |
author_sort | Rundo, Leonardo |
collection | PubMed |
description | BACKGROUND: Pathological response to neoadjuvant treatment for patients with high-grade serous ovarian carcinoma (HGSOC) is assessed using the chemotherapy response score (CRS) for omental tumor deposits. The main limitation of CRS is that it requires surgical sampling after initial neoadjuvant chemotherapy (NACT) treatment. Earlier and non-invasive response predictors could improve patient stratification. We developed computed tomography (CT) radiomic measures to predict neoadjuvant response before NACT using CRS as a gold standard. METHODS: Omental CT-based radiomics models, yielding a simplified fully interpretable radiomic signature, were developed using Elastic Net logistic regression and compared to predictions based on omental tumor volume alone. Models were developed on a single institution cohort of neoadjuvant-treated HGSOC (n = 61; 41% complete response to NCT) and tested on an external test cohort (n = 48; 21% complete response). RESULTS: The performance of the comprehensive radiomics models and the fully interpretable radiomics model was significantly higher than volume-based predictions of response in both the discovery and external test sets when assessed using G-mean (geometric mean of sensitivity and specificity) and NPV, indicating high generalizability and reliability in identifying non-responders when using radiomics. The performance of a fully interpretable model was similar to that of comprehensive radiomics models. CONCLUSIONS: CT-based radiomics allows for predicting response to NACT in a timely manner and without the need for abdominal surgery. Adding pre-NACT radiomics to volumetry improved model performance for predictions of response to NACT in HGSOC and was robust to external testing. A radiomic signature based on five robust predictive features provides improved clinical interpretability and may thus facilitate clinical acceptance and application. |
format | Online Article Text |
id | pubmed-9243357 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-92433572022-07-01 Clinically Interpretable Radiomics-Based Prediction of Histopathologic Response to Neoadjuvant Chemotherapy in High-Grade Serous Ovarian Carcinoma Rundo, Leonardo Beer, Lucian Escudero Sanchez, Lorena Crispin-Ortuzar, Mireia Reinius, Marika McCague, Cathal Sahin, Hilal Bura, Vlad Pintican, Roxana Zerunian, Marta Ursprung, Stephan Allajbeu, Iris Addley, Helen Martin-Gonzalez, Paula Buddenkotte, Thomas Singh, Naveena Sahdev, Anju Funingana, Ionut-Gabriel Jimenez-Linan, Mercedes Markowetz, Florian Brenton, James D. Sala, Evis Woitek, Ramona Front Oncol Oncology BACKGROUND: Pathological response to neoadjuvant treatment for patients with high-grade serous ovarian carcinoma (HGSOC) is assessed using the chemotherapy response score (CRS) for omental tumor deposits. The main limitation of CRS is that it requires surgical sampling after initial neoadjuvant chemotherapy (NACT) treatment. Earlier and non-invasive response predictors could improve patient stratification. We developed computed tomography (CT) radiomic measures to predict neoadjuvant response before NACT using CRS as a gold standard. METHODS: Omental CT-based radiomics models, yielding a simplified fully interpretable radiomic signature, were developed using Elastic Net logistic regression and compared to predictions based on omental tumor volume alone. Models were developed on a single institution cohort of neoadjuvant-treated HGSOC (n = 61; 41% complete response to NCT) and tested on an external test cohort (n = 48; 21% complete response). RESULTS: The performance of the comprehensive radiomics models and the fully interpretable radiomics model was significantly higher than volume-based predictions of response in both the discovery and external test sets when assessed using G-mean (geometric mean of sensitivity and specificity) and NPV, indicating high generalizability and reliability in identifying non-responders when using radiomics. The performance of a fully interpretable model was similar to that of comprehensive radiomics models. CONCLUSIONS: CT-based radiomics allows for predicting response to NACT in a timely manner and without the need for abdominal surgery. Adding pre-NACT radiomics to volumetry improved model performance for predictions of response to NACT in HGSOC and was robust to external testing. A radiomic signature based on five robust predictive features provides improved clinical interpretability and may thus facilitate clinical acceptance and application. Frontiers Media S.A. 2022-06-16 /pmc/articles/PMC9243357/ /pubmed/35785153 http://dx.doi.org/10.3389/fonc.2022.868265 Text en Copyright © 2022 Rundo, Beer, Escudero Sanchez, Crispin-Ortuzar, Reinius, McCague, Sahin, Bura, Pintican, Zerunian, Ursprung, Allajbeu, Addley, Martin-Gonzalez, Buddenkotte, Singh, Sahdev, Funingana, Jimenez-Linan, Markowetz, Brenton, Sala and Woitek https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Oncology Rundo, Leonardo Beer, Lucian Escudero Sanchez, Lorena Crispin-Ortuzar, Mireia Reinius, Marika McCague, Cathal Sahin, Hilal Bura, Vlad Pintican, Roxana Zerunian, Marta Ursprung, Stephan Allajbeu, Iris Addley, Helen Martin-Gonzalez, Paula Buddenkotte, Thomas Singh, Naveena Sahdev, Anju Funingana, Ionut-Gabriel Jimenez-Linan, Mercedes Markowetz, Florian Brenton, James D. Sala, Evis Woitek, Ramona Clinically Interpretable Radiomics-Based Prediction of Histopathologic Response to Neoadjuvant Chemotherapy in High-Grade Serous Ovarian Carcinoma |
title | Clinically Interpretable Radiomics-Based Prediction of Histopathologic Response to Neoadjuvant Chemotherapy in High-Grade Serous Ovarian Carcinoma |
title_full | Clinically Interpretable Radiomics-Based Prediction of Histopathologic Response to Neoadjuvant Chemotherapy in High-Grade Serous Ovarian Carcinoma |
title_fullStr | Clinically Interpretable Radiomics-Based Prediction of Histopathologic Response to Neoadjuvant Chemotherapy in High-Grade Serous Ovarian Carcinoma |
title_full_unstemmed | Clinically Interpretable Radiomics-Based Prediction of Histopathologic Response to Neoadjuvant Chemotherapy in High-Grade Serous Ovarian Carcinoma |
title_short | Clinically Interpretable Radiomics-Based Prediction of Histopathologic Response to Neoadjuvant Chemotherapy in High-Grade Serous Ovarian Carcinoma |
title_sort | clinically interpretable radiomics-based prediction of histopathologic response to neoadjuvant chemotherapy in high-grade serous ovarian carcinoma |
topic | Oncology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9243357/ https://www.ncbi.nlm.nih.gov/pubmed/35785153 http://dx.doi.org/10.3389/fonc.2022.868265 |
work_keys_str_mv | AT rundoleonardo clinicallyinterpretableradiomicsbasedpredictionofhistopathologicresponsetoneoadjuvantchemotherapyinhighgradeserousovariancarcinoma AT beerlucian clinicallyinterpretableradiomicsbasedpredictionofhistopathologicresponsetoneoadjuvantchemotherapyinhighgradeserousovariancarcinoma AT escuderosanchezlorena clinicallyinterpretableradiomicsbasedpredictionofhistopathologicresponsetoneoadjuvantchemotherapyinhighgradeserousovariancarcinoma AT crispinortuzarmireia clinicallyinterpretableradiomicsbasedpredictionofhistopathologicresponsetoneoadjuvantchemotherapyinhighgradeserousovariancarcinoma AT reiniusmarika clinicallyinterpretableradiomicsbasedpredictionofhistopathologicresponsetoneoadjuvantchemotherapyinhighgradeserousovariancarcinoma AT mccaguecathal clinicallyinterpretableradiomicsbasedpredictionofhistopathologicresponsetoneoadjuvantchemotherapyinhighgradeserousovariancarcinoma AT sahinhilal clinicallyinterpretableradiomicsbasedpredictionofhistopathologicresponsetoneoadjuvantchemotherapyinhighgradeserousovariancarcinoma AT buravlad clinicallyinterpretableradiomicsbasedpredictionofhistopathologicresponsetoneoadjuvantchemotherapyinhighgradeserousovariancarcinoma AT pinticanroxana clinicallyinterpretableradiomicsbasedpredictionofhistopathologicresponsetoneoadjuvantchemotherapyinhighgradeserousovariancarcinoma AT zerunianmarta clinicallyinterpretableradiomicsbasedpredictionofhistopathologicresponsetoneoadjuvantchemotherapyinhighgradeserousovariancarcinoma AT ursprungstephan clinicallyinterpretableradiomicsbasedpredictionofhistopathologicresponsetoneoadjuvantchemotherapyinhighgradeserousovariancarcinoma AT allajbeuiris clinicallyinterpretableradiomicsbasedpredictionofhistopathologicresponsetoneoadjuvantchemotherapyinhighgradeserousovariancarcinoma AT addleyhelen clinicallyinterpretableradiomicsbasedpredictionofhistopathologicresponsetoneoadjuvantchemotherapyinhighgradeserousovariancarcinoma AT martingonzalezpaula clinicallyinterpretableradiomicsbasedpredictionofhistopathologicresponsetoneoadjuvantchemotherapyinhighgradeserousovariancarcinoma AT buddenkottethomas clinicallyinterpretableradiomicsbasedpredictionofhistopathologicresponsetoneoadjuvantchemotherapyinhighgradeserousovariancarcinoma AT singhnaveena clinicallyinterpretableradiomicsbasedpredictionofhistopathologicresponsetoneoadjuvantchemotherapyinhighgradeserousovariancarcinoma AT sahdevanju clinicallyinterpretableradiomicsbasedpredictionofhistopathologicresponsetoneoadjuvantchemotherapyinhighgradeserousovariancarcinoma AT funinganaionutgabriel clinicallyinterpretableradiomicsbasedpredictionofhistopathologicresponsetoneoadjuvantchemotherapyinhighgradeserousovariancarcinoma AT jimenezlinanmercedes clinicallyinterpretableradiomicsbasedpredictionofhistopathologicresponsetoneoadjuvantchemotherapyinhighgradeserousovariancarcinoma AT markowetzflorian clinicallyinterpretableradiomicsbasedpredictionofhistopathologicresponsetoneoadjuvantchemotherapyinhighgradeserousovariancarcinoma AT brentonjamesd clinicallyinterpretableradiomicsbasedpredictionofhistopathologicresponsetoneoadjuvantchemotherapyinhighgradeserousovariancarcinoma AT salaevis clinicallyinterpretableradiomicsbasedpredictionofhistopathologicresponsetoneoadjuvantchemotherapyinhighgradeserousovariancarcinoma AT woitekramona clinicallyinterpretableradiomicsbasedpredictionofhistopathologicresponsetoneoadjuvantchemotherapyinhighgradeserousovariancarcinoma |